(1RVMD.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1RVMD -
1RVMD.MI Key Statistics, Chart & Performance
The current stock price of 1RVMD.MI is 65.5 null.
1RVMD.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.78 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About 1RVMD.MI
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
700 Saginaw Dr
Redwood City CALIFORNIA US
Employees: 534
Phone: 14157663638
/ 1RVMD.MI FAQ
What does do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Can you provide the latest stock price for ?
The current stock price of 1RVMD.MI is 65.5 null.
What is the dividend status of ?
1RVMD.MI does not pay a dividend.
How is the ChartMill rating for ?
1RVMD.MI has a ChartMill Technical rating of 1 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
What do analysts say about (1RVMD.MI) stock?
26 analysts have analysed 1RVMD.MI and the average price target is 68.98 null. This implies a price increase of 5.31% is expected in the next year compared to the current price of 65.5.
What is the employee count for 1RVMD stock?
(1RVMD.MI) currently has 534 employees.
Can you provide the ownership details for 1RVMD stock?
You can find the ownership structure of (1RVMD.MI) on the Ownership tab.
1RVMD.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1RVMD.MI.
1RVMD.MI Financial Highlights
Over the last trailing twelve months 1RVMD.MI reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS decreased by -44.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| Debt/Equity | 0.16 |
1RVMD.MI Forecast & Estimates
26 analysts have analysed 1RVMD.MI and the average price target is 68.98 null. This implies a price increase of 5.31% is expected in the next year compared to the current price of 65.5.
For the next year, analysts expect an EPS growth of -53.26% and a revenue growth 1200% for 1RVMD.MI